Healthcare Review: Nu Skin Enterprises, Conceptus, Dendreon Corporation, Vascular Solutions, Elan Corporation Print E-mail
By Staff and Wire Reports   
Wednesday, 06 February 2013 15:00

U.S. stocks were little changed on Wednesday as investors, without any major economic reports to guide them, awaited fresh incentives to trade after rallies took the S&P 500 to five-year highs.

Transportation stocks were among the worst performers, weighed down by a 10 percent drop in CH Robinson Worldwide (CHRW) to $60.40 after the freight transport company posted a lower-than-expected adjusted quarterly profit. Following are the notable movers at mid day on Wednesday:-

Nu Skin Enterprises, Inc. (NYSE:NUS) stock fell 2.98% to $41.71 after the company reported fourth-quarter net income of $59.23 million, or $0.97 per share, versus last year's $49.52 million, or $0.76 per share. Analysts expected earnings per share of $0.94 for the quarter. Revenue of $588.2 million for the quarter, were 19 percent higher than $495.3 million in the prior-year period. Analysts estimated revenues of $579.50 million for the quarter.

Conceptus, Inc. (NASDAQ:CPTS)
stock gained 8.45% to $23.11 after the company yesterday announced that it has initiated enrollment in its European clinical study designed to support the company's CE Mark application for its next generation Essure device.

Additionally, the company yesterday announced that for fiscal 2013, it expects sales to be in the range of $155-$159 million, adjusted EBITDA to be in the range of $34-$37 million and net income to be in the range of $7.02-$8.67 million. Analysts were expecting the Company to report revenue of $160 million, EBITDA of $31 million and net income of $6.54 million for fiscal 2013.

Dendreon Corporation (NASDAQ:DNDN) shares climbed 6.17% to $6.53. The company announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.m. ET to review fourth quarter and full year 2012 financial results.

Additionally, the company, early this month, announced preliminary revenues for the fourth quarter ended December 31, 2012. Net product revenue for the quarter is expected to be approximately $85.5 million, which includes an approximate $3.8 million favorable adjustment to the Company’s chargebacks reserve due to a change in estimate. On a pro-forma basis, excluding this adjustment, revenue for the quarter is expected to be approximately $81.6 million, up 5% on a sequential basis.

Vascular Solutions, Inc. (NASDAQ:VASC)
shares dropped 8.01% to $15.16 in the early hour after the company yesterday announced that for fiscal 2013, it expects net revenue to between $106-$110 million, net earnings to between $0.66-$0.70 per fully diluted share. For the first quarter of 2013, it expects net revenue of between $26.0-$27.0 million and net earnings to be between $0.15-$0.16 per diluted share. Analysts are expecting the Company to report revenue of $109 million and EPS of $0.68 for fiscal 2013; revenue of $26.7 million and EPS of $0.16 for first quarter of 2013.

Elan Corporation, plc (ADR) (NYSE:ELN)
shares declined 8.13% to $9.61 after the company today announced that it has agreed to restructure the Tysabri collaboration with Biogen Idec. Under the terms of the agreement, Elan will move from the current 50:50 business collaboration to an upfront payment of $3.25 billion and a double digit tiered royalty structure for the complete asset. Highlights of Transaction Upon Closing: Up front cash payment of $3.25 billion to Elan First 12 months: royalty of 12% of Tysabri global net sales (all indications) Tiered royalty structure after 12 months 18% on up to $2 billion of global net sales (all indications) 25% on over $2 billion of global net sales (all indications) Biogen Idec will have full ownership and control of Tysabri Current 50:50 collaboration will terminate Provides tax efficient capital and long term cash flow to Elan.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter